Geode Capital Management
STOK icon

Geode Capital Management’s Stoke Therapeutics STOK Stock Holding History

Geode Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40.8M Buy
1,568,371
+44,062
+3% +$1.33M ﹤0.01% 1704
2026
Q2 		$49.9M Buy
1,524,309
+202,049
+15% +$6.48M ﹤0.01% 1629
2026
Q1 		$43.1M Buy
1,322,260
+156,115
+13% +$5.12M ﹤0.01% 1574
2025
Q4 		$37M Buy
1,166,145
+19,145
+2% +$576K ﹤0.01% 1668
2025
Q3 		$27M Buy
1,147,000
+174,079
+18% +$2.98M ﹤0.01% 1845
2025
Q2 		$11M Buy
972,921
+70,935
+8% +$674K ﹤0.01% 2298
2025
Q1 		$6M Buy
901,986
+24,891
+3% +$232K ﹤0.01% 2572
2024
Q4 		$9.7M Buy
877,095
+6,264
+0.7% +$77K ﹤0.01% 2401
2024
Q3 		$10.7M Buy
870,831
+76,661
+10% +$1.09M ﹤0.01% 2337
2024
Q2 		$10.7M Buy
794,170
+154,363
+24% +$2.08M ﹤0.01% 2280
2024
Q1 		$8.64M Buy
639,807
+24,083
+4% +$146K ﹤0.01% 2409
2023
Q4 		$3.24M Buy
615,724
+24,607
+4% +$105K ﹤0.01% 2911
2023
Q3 		$2.33M Sell
591,117
-8,663
-1% -$57K ﹤0.01% 3023
2023
Q2 		$6.38M Buy
599,780
+113,100
+23% +$1.2M ﹤0.01% 2560
2023
Q1 		$4.05M Buy
486,680
+12,456
+3% +$112K ﹤0.01% 2729
2022
Q4 		$4.38M Buy
474,224
+13,969
+3% +$145K ﹤0.01% 2734
2022
Q3 		$5.91M Buy
460,255
+16,446
+4% +$262K ﹤0.01% 2580
2022
Q2 		$5.86M Buy
443,809
+8,038
+2% +$122K ﹤0.01% 2613
2022
Q1 		$9.17M Buy
435,771
+59,617
+16% +$1.19M ﹤0.01% 2405
2021
Q4 		$9.02M Buy
376,154
+12,819
+4% +$306K ﹤0.01% 2517
2021
Q3 		$9.24M Buy
363,335
+7,089
+2% +$198K ﹤0.01% 2502
2021
Q2 		$12M Buy
356,246
+63,210
+22% +$2.23M ﹤0.01% 2334
2021
Q1 		$11.4M Buy
293,036
+21,871
+8% +$1.25M ﹤0.01% 2271
2020
Q4 		$16.8M Buy
271,165
+68,976
+34% +$3.16M ﹤0.01% 1830
2020
Q3 		$6.77M Buy
202,189
+42,245
+26% +$1.21M ﹤0.01% 2211
2020
Q2 		$3.81M Sell
159,944
-25,912
-14% -$615K ﹤0.01% 2495
2020
Q1 		$4.26M Buy
185,856
+66,139
+55% +$1.63M ﹤0.01% 2235
2019
Q4 		$3.39M Buy
119,717
+6,965
+6% +$175K ﹤0.01% 2686
2019
Q3 		$2.42M Buy
+112,752
New +$3.14M ﹤0.01% 2820

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Geode Capital Management's STOK Position: Q3 2026 in Review

Geode Capital Management increased its Stoke Therapeutics (STOK) stake by 2.9% in Q3 2026, buying an estimated $1.33M and bringing the position to 1,568,371 shares worth $40.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Geode Capital Management first reported a position in STOK in Q3 2019 and has held it in 29 quarters since. The position peaked at $49.9M in Q2 2026. 57 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Geode Capital Management held 1,568,371 shares of Stoke Therapeutics worth $40.8M as of Q3 2026.
  • Geode Capital Management bought 44,062 Stoke Therapeutics shares in Q3 2026, an estimated $1.33M.
  • Stoke Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #1704 holding.
  • Geode Capital Management first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 29 quarters since.
  • Geode Capital Management's Stoke Therapeutics position peaked at $49.9M in Q2 2026.
  • 57 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.